Literature DB >> 9294492

Craniofacial growth in short children born small for gestational age: effect of growth hormone treatment.

R van Erum1, M Mulier, C Carels, G Verbeke, F de Zegher.   

Abstract

The effects of growth hormone (GH) therapy in children have yet to be completely catalogued. In the present study, the effect of high-dose GH treatment on craniofacial growth was evaluated once yearly in 21 pre-pubertal, non-GH-deficient children born small for gestational age. These children were randomly allocated to be either untreated or treated with GH at a daily subcutaneous dose of 0.2 or 0.3 IU/kg for 2 yrs. The group consisted of 12 girls and 9 boys with a mean age of 5.1 yr (range, 2 to 8 yr), bone age of 3.4 yr, and height SDS of -3.6. At the start of the study, all children showed an overall delay of craniofacial growth. This cohort of short children born small for gestational age showed a small SNB angle and a large ANB angle; all other angular measurements were within normal range. GH treatment accelerated growth in several craniofacial components, especially the posterior total facial height, the cranial base length, and the overall mandibular length. The increase of the mandibular length increased the SNB angle; no other angular measurements were affected. Age at start of treatment differently influenced the increase in posterior and total cranial base length, the increase in mandibular corpus length, and the position of the mandible in relation to the cranial base. Although GH treatment for 2 yrs led to a craniofacial growth acceleration, the position of the mandible in relation to the cranial base and the craniofacial size in lateral aspect were not normalized in the majority of the GH-treated children. No signs of disproportional growth were evidenced after 2 yrs of high-dose GH treatment. In conclusion, short pre-pubertal SGA children display an overall delay of linear craniofacial growth and a retrognathic mandible. High-dose GH treatment over 2 yrs leads to craniofacial catch-up growth, which is pronounced in regions where interstitial cartilage is involved and results in a less convex face in profile.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294492     DOI: 10.1177/00220345970760091001

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  5 in total

1.  Ontogenetic changes of craniofacial complex in Turner syndrome patients treated with growth hormone.

Authors:  Jovana Juloski; Branislav Glisic; Ivana Scepan; Jelena Milasin; Katarina Mitrovic; Marko Babic
Journal:  Clin Oral Investig       Date:  2012-09-23       Impact factor: 3.573

2.  Growth hormone treatment does not affect incidences of middle ear disease or hearing loss in infants and toddlers with Turner syndrome.

Authors:  Marsha L Davenport; Jackson Roush; Chunhua Liu; Anthony J Zagar; Erica Eugster; Sharon Travers; Patricia Y Fechner; Charmian A Quigley
Journal:  Horm Res Paediatr       Date:  2010-04-27       Impact factor: 2.852

3.  Cephalometric features in isolated growth hormone deficiency.

Authors:  Luiz Alves Oliveira-Neto; Mariade de Fátima B Melo; Alexandre A Franco; Alaíde H A Oliveira; Anita H O Souza; Eugênia H O Valença; Isabela M P A Britto; Roberto Salvatori; Manuel H Aguiar-Oliveira
Journal:  Angle Orthod       Date:  2011-02-21       Impact factor: 2.079

4.  Growth Hormone and Craniofacial Tissues. An update.

Authors:  George Litsas
Journal:  Open Dent J       Date:  2015-01-30

Review 5.  New therapeutics in promoting and modulating mandibular growth in cases with mandibular hypoplasia.

Authors:  Tarek El-Bialy; Adel Alhadlaq
Journal:  Biomed Res Int       Date:  2013-05-29       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.